文献速递糖尿病肥胖与代谢综合征

每周一次司美格鲁肽对比恩格列净联合二甲双胍治疗2型糖尿病的疗效:患者水平Meta分析

Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

本研究采用患者个体数据与Meta回归方法,间接比较每周一次司美格鲁肽1 mg与每日一次恩格列净25 mg在二甲双胍单药控制不佳的2型糖尿病患者中的疗效。结果显示,司美格鲁肽较恩格列净显著降低HbA1c(估计治疗差异-0.61%-point,95%CI -0.72至-0.49)和体重(-1.65 kg,95%CI -2.22至-1.08),两者P均<0.0001,且更多患者达到HbA1c目标和体重下降应答。

要点

  • 每周一次司美格鲁肽1 mg较每日一次恩格列净25 mg显著降低HbA1c,估计治疗差异为-0.61%-point(95%CI -0.72至-0.49,P<0.0001)。
  • 每周一次司美格鲁肽1 mg较每日一次恩格列净25 mg显著降低体重,估计治疗差异为-1.65 kg(95%CI -2.22至-1.08,P<0.0001)。
  • 司美格鲁肽组达到HbA1c目标和体重下降应答的患者比例显著高于恩格列净组。

核心结论

  • 本间接比较提示,在二甲双胍单药治疗基础上,每周一次司美格鲁肽1 mg较每日一次恩格列净25 mg在2型糖尿病患者中提供更优的HbA1c和体重降低。

研究设计与样本

  • 采用患者个体数据和Meta回归方法进行间接比较,纳入二甲双胍单药治疗且随机接受每周一次司美格鲁肽1 mg(SUSTAIN 2、3、8试验)或每日一次恩格列净25 mg(PIONEER 2试验)的2型糖尿病患者。
  • Meta回归分析校正了潜在预后因素和效应修饰因素。
  • 司美格鲁肽组n=995,恩格列净组n=410,两组基线特征相似。

主要发现

  • 司美格鲁肽较恩格列净显著降低平均HbA1c,估计治疗差异为-0.61%-point(95%CI -0.72至-0.49,P<0.0001)。
  • 司美格鲁肽较恩格列净显著降低体重,估计治疗差异为-1.65 kg(95%CI -2.22至-1.08,P<0.0001)。
  • 司美格鲁肽组达到HbA1c目标和体重下降应答的患者比例显著高于恩格列净组。
  • 补充分析支持上述结果的稳健性。

关键数值与推荐

  • 主要疗效结局为从基线至治疗结束(约1年)的HbA1c(%-point)和体重(kg)变化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: No head-to-head trials have directly compared once-weekly (OW) semaglutide, a human glucagon-like peptide-1 analog, with empagliflozin, a sodium-glucose co-transporter-2 inhibitor, in type 2 diabetes (T2D). OBJECTIVE: We indirectly compared the efficacy of OW semaglutide 1 mg vs once-daily (OD) empagliflozin 25 mg in patients with T2D inadequately controlled on metformin monotherapy, using individual patient data (IPD) and meta-regression methodology. DESIGN, SETTING, PARTICIPANTS, AND INTERVENTIONS: IPD for patients with T2D receiving metformin monotherapy and randomized to OW semaglutide 1 mg (SUSTAIN 2, 3, 8 trials), or to OD empagliflozin 25 mg (PIONEER 2 trial) were included. Meta-regression analyses were adjusted for potential prognostic factors and effect modifiers. MAIN OUTCOME MEASURES: The primary efficacy outcomes were change from baseline to end-of-treatment (~1 year) in HbA1c (%-point) and body weight (kg). Responder outcomes and other clinically relevant efficacy measures were analyzed. RESULTS: Baseline characteristics were similar between OW semaglutide (n = 995) and empagliflozin (n = 410). Our analyses showed that OW semaglutide significantly reduced mean HbA1c and body weight vs empagliflozin (estimated treatment difference: -0.61%-point [95% confidence interval (CI): -0.72; -0.49] and -1.65 kg [95% CI: -2.22; -1.08], respectively; both P < 0.0001). Complementary analyses supported the robustness of these results. A significantly greater proportion of patients on OW semaglutide vs empagliflozin also achieved HbA1c targets and weight-loss responses. CONCLUSIONS: This indirect comparison suggests that OW semaglutide 1 mg provides superior reductions in HbA1c and body weight vs OD empagliflozin 25 mg in patients with T2D when added to metformin monotherapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Lingvay I, Capehorn MS, Catarig AM, et al. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. J Clin Endocrinol Metab. 2020. PMID: 32827435. doi:10.1210/clinem/dgaa577

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。